Drug Trial Radar · NCT03001544
Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer
Last checked: Nov 19, 2026Latest source record: Dec 23, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
24
Actual
Start
Jul 2015
Primary completion
Jun 2016
Study completion Jun 2017
Sponsor
- Lead sponsor
- Translational Sciences, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to determine the safety, pharmacokinetics and pharmacodynamics of a single intravenous dose of TS23 in healthy adults.
Conditions
- Thrombosis
- Cerebral Ischemia
- Venous Thrombosis
- Pulmonary Embolism
- Myocardial Infarction
Interventions
TS23Biological
comparison of different doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and severity of adverse events post-doseTime frame: 10 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.